Business Consulting Services

  Nasal polyposis  is small, benign (noncancerous) drop-like growths appearing in the mucosa (lining tissues) of the nose and may block the nasal passageway. Nasal polyposis tends to be present on both sides of the nasal cavity. Small nasal polyps may not reflect any symptoms, but the larger growths or groups of nasal polyps can block the nasal passages or lead to breathing problems, a lost sense of smell, and frequent infections. Nasal Polyposis Epidemiology Segmentation in the 7MM ·           Prevalent Cases of Chronic Rhinosinusitis ·           Diagnosed Prevalent Cases of Chronic Rhinosinusitis ·           Diagnosed Prevalent Cases of Nasal Polyposis ·           Gender-specific Diagnosed Prevalent Cases of Nasal Polyposis Nasal Polyposis Epidemiological Insights Observed in the 7MM (2021) · ...

  Carbapenem-resistant Enterobacteriaceae Infection Market Carbapenem-resistant Enterobacteriaceae Infection Market Size, Insights report delivers an understanding of the Carbapenem-resistant Enterobacteriaceae Infection forecasted epidemiology Sarcopenia Market DelveInsight's Sarcopenia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Sarcopenia, historical and forecasted epidemiology. Opioid-related Disorders Market DelveInsight's Opioid-related Disorders Market Insights, Epidemiology, and Market Forecast report deliver an in-depth understanding of the Opioid-related Disorders forecasted epidemiology. Pediatric Growth Hormone Deficiency PGHD Market Pediatric Growth Hormone Deficiency Market Insights, Epidemiology, and Market Forecast report delivers an understanding of the Pediatric Growth Hormone Deficiency forecasted epidemiology. Oncolytic Virus Cancer Ther...

    SurVaxM Highlights: ASCO 2022 Positive results from the "SURVIVE" (Phase II a) research in people with newly discovered glioblastoma were given by Mimivax (Abstract #2037). SurVaxM mechanism of action: Immunostimulants A cell-survival protein found in 95 percent of glioblastomas and many other malignancies, survivin is the target of SurVaxM (MimiVax), a first-in-class, proprietary peptide mimic immunogen. The SurVaxM immunotherapy for newly diagnosed glioblastoma Phase IIa (Survive) results was presented at ASCO 2022. A total of 63 patients with freshly diagnosed glioblastoma participated in the single-arm Survive research, with a median age of 60 for those who had just undergone their first round of chemoradiation. Each patient had a craniotomy, radiation therapy, and temozolomide treatment prior to receiving the SurVaxM priming dosages. It's interesting to note that, overall, 41 percent of patients survived for at least three years after receiving a glioblastoma d...